Literature DB >> 6186412

Some considerations of methodology and standardization of apolipoprotein B immunoassays.

M Rosseneu, R Vercaemst, K K Steinberg, G R Cooper.   

Abstract

Apolipoprotein B, the major protein component of very-low-density (VLDL) and low-density (LDL) lipoproteins in serum, is being widely measured in serum, to help assess risk of cardiovascular disease. Standardization has proven difficult because of the physical and immunochemical heterogeneity of LDL and VLDL, the masking of antigenic determinants of LDL and VLDL, the insolubility of apolipoprotein B, the instability of lipoprotein reference materials, and the multiplicity of analytical methods. Here we have examined the literature and collected current information from lipoprotein scientists to determine the problems--and the ways investigators have attempted to solve them--in preparation, storage, and use of standards and anti-apolipoprotein B sera, analytical procedures and reagents, and the nature of apolipoprotein B in serum. Standardization appears possible with development of stable reference materials that are applicable to the various analytical methods, controlled immunochemical reaction conditions, and establishment of a selected interim reference method for use as a point of reference.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186412

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Heterogeneity of high-density lipoprotein particles and insulin output during oral glucose tolerance test in men with coronary artery disease.

Authors:  J Iwanejko; M Kwaśniak; I Wybrańska; J Hartwich; I Guevara; A Zdzienicka; O Kruszelnicka-Kwiatkowska; W Piwowarska; B Miszczuk-Jamska; A Dembińska-Kieć
Journal:  Acta Diabetol       Date:  1996-03       Impact factor: 4.280

2.  Determination of serum apolipoprotein B by competitive enzyme-linked immunoassay.

Authors:  H Reisinger; W Strobl; B Hubrich; K Widhalm
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Plasma and lipoprotein lipids and apolipoproteins AI, AII and B in patients with chronic airflow limitation.

Authors:  C H Bolton; E Mulloy; J Harvey; L G Downs; M Hartog
Journal:  J R Soc Med       Date:  1989-02       Impact factor: 5.344

4.  Influence of dietary factors on the plasma lipoprotein composition and content in neonates.

Authors:  J P Van Biervliet; M Rosseneu; H Caster
Journal:  Eur J Pediatr       Date:  1986-02       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.